 eFitnessNow [1] |
FDA extended time to review saxagliptin for treatment of diabetes [3] [2]
Endocrine Today, NJ The FDA has extended the date of the Prescription Drug User Fee Act from April 30, 2009 to July 30, 2009, stating that additional time is needed to complete the review of saxagliptin for the treatment of type 2 diabetes [3]. … FDA extends timeline to approve diabetes [4] drug of Bristol-Myers … RTT News diabetes [5]_drug_Onglyza.html&cid=1339678364&ei=Hgf1SbukGqKcggOr9_yGDA&usg=AFQjCNEAsmMGKXwdDF-1ASODvUHyFyKw5A”>FDA wants more time to review diabetes drug Onglyza Philadelphia Inquirer AstraZeneca: FDA Extends Timeline For Onglyza NDA To July 30 [6] Wall Street Journal EfluxMedia News [7] – Pharma Times [8] all 59 news articles |